<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799511</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00346-41</org_study_id>
    <nct_id>NCT02799511</nct_id>
  </id_info>
  <brief_title>Biomarkers for the Diagnosis of Transient Ischemic Attack</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>Biomarkers for the Diagnosis of Transient Ischemic Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A transient ischemic attack (TIA) should be considered an emergency prevention opportunity in&#xD;
      order to avoid recurrence as cerebral infarction (CI) serious (fatal or disabling). Indeed,&#xD;
      about 20% of patients who have IC had in previous days or weeks, a TIA, which can be defined&#xD;
      as a brief episode of cerebral dysfunction (or eye) do not result in permanent brain damage&#xD;
      and thus no sequelae. Moreover, about 20% of ischemic events observed in practice are AIT.&#xD;
      Despite the progress achieved in the treatment in the acute phase of an IC, prevention&#xD;
      remains the most effective way to fight against this disease. This prevention can be put in&#xD;
      place before the occurrence of a first IC, or after a first IC, especially when minor as a&#xD;
      TIA.&#xD;
&#xD;
      However, the diagnosis of TIA remains particularly difficult and it is necessary now to&#xD;
      identify new tools for the diagnosis of transient ischemic attack. Our study focused on the&#xD;
      identification of one or more molecules (called biological markers or biomarkers) present in&#xD;
      the bloodstream of patients, which will serve to facilitate the differential diagnosis of&#xD;
      patients with TIA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in proteomic analysis from MPs or from plasma.</measure>
    <time_frame>baseline and 72h after TAI and 90 days after TAI</time_frame>
    <description>Identify one or more markers of transient ischemic attack by a proteomic analysis from MPs or from plasma.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Ischemic Attack, Transient</condition>
  <arm_group>
    <arm_group_label>protein expression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>protein expression</intervention_name>
    <description>Differential protein expression between the period of acute cerebral ischemia and the control period</description>
    <arm_group_label>protein expression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TIA lasting 18h&#xD;
&#xD;
          -  NIHSS &lt; 0&#xD;
&#xD;
          -  MRI diffusion hypersignal less than 5 ml&#xD;
&#xD;
          -  follow up during 3 month&#xD;
&#xD;
          -  written informed consent prior to any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  major comorbidity (cancer, chronic infection)&#xD;
&#xD;
          -  recent trauma (less than 30 days) (cranial or extracranial)&#xD;
&#xD;
          -  Surgical or endovascular recent surgery(within 30 days).&#xD;
&#xD;
          -  Any old brain injury&#xD;
&#xD;
          -  Any acute pathology likely to induce inflammation, hemostasis disorders ...&#xD;
&#xD;
          -  Contraindications to MRI: Patients with a pacemaker, an implanted material activated&#xD;
             by an electrical, magnetic or mechanical carriers hemostatic clips intracerebral&#xD;
             aneurysms or carotid arteries, bearing orthopedic implants, claustrophobic ...&#xD;
&#xD;
          -  Patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biological markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

